Bradykinin and cardiac protection

Advances in Experimental Medicine and Biology

Volumn 432, Issue , 1997, Pages 159-172

  Gohlke, Peter ^a   Tschöpe, Garsten ^a,b   Unger, Thomas ^a  

^a UNIVERSITY OF KIEL   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN 2 RECEPTOR; BRADYKININ; BRADYKININ B1 RECEPTOR; BRADYKININ B2 RECEPTOR; BRADYKININ B2 RECEPTOR ANTAGONIST; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ICATIBANT; KALLIKREIN; KININ; LOSARTAN; MOEXIPRIL; PERINDOPRIL; RAMIPRIL;

CONFERENCE PAPER; CORONARY ARTERY BLOOD FLOW; DRUG EFFECT; HEART INFARCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE BLOOD FLOW; HEART MUSCLE CAPILLARY; HEART MUSCLE ISCHEMIA; HEART MUSCLE METABOLISM; HEART PROTECTION; HUMAN; HYPERTENSION; INTRACORONARY INFUSION; KALLIKREIN KININ SYSTEM; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0031455060     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4615-5385-4_17     Document Type: Conference Paper

References (21)

1. Bhoola KD, Figuero CD, Worthy K: Bioregulation of kinins: kallikreins, kininogens, and kininases. Pharmacol Rev 1992;44 (1):1-80
2. Linz W, Wiemer G, Gohlke P, Unger T, Schölkens BA: Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors. Pharmacol Rev 1995;47:25-49
3. Margolius HS: Kallikreins and kinins. Molecular characteristics and cellular and tissue responses. Diabetes 1996;45(Suppl. 1):S14-S19
4. Scicli AG, Mindrooiu T, Scicli G, Carretero OA: Blood kinins their concentrations in normal subjects and in patients with congenital deficiency in plasma prekallikrein and kininogen. J Lab Clin 1982; 100:81-93
5. Shimamoto K, Ando T, Tanaka S, Nakahashi Y, Nishitani T, Hosoda S, Ishida H, Iimura O: An improved method for the determination of human blood kinin levels by sensitive kinin radioimmunoassay. Endocrinol Jpn 1982;29:487-494
6. Ryan JW, Robelero J, Stewart JM: Inactivation of bradykinin in the pulmonary circulation. Biochem J 1986; 110:795-797
7. Farhy RD, Carretero OA, Ho K-L, Scicli AG: Role of kinins and nitric oxide in the effects of angiotensin converting enzyme inhibitors on neointima formation. Circ Res 1993;72:1202-1210
8. Becker RHA, Wiemer G, Linz W: Preservation of endothelial function by ramipril in rabbits on a long-term atherogenic diet. J Cardiovasc Pharmacol 1991;18 (suppl. 2):S110-S115
9. Schölkens BA, Linz W, König W: Effects of the angiotensin converting enzyme inhibitor, ramipril, in isolated ischaemic rat heart are abolished by a bradykinin antagonist. J Hypertens 1988;(suppl. 4):S25-S28
10. Daniell HB, Carson RR, Ballard KD, Thomas GR, Privitera PJ: Effects of captopril on limiting infarct size in conscious dogs. J Cardiovasc Pharmacol 1984;6:1043-1047
11. Ertl G: Angiotensin converting enzyme inhibitors and ischemic heart disease. Eur Heart J 1988;9:716-727
12. Kass RW, Kotler MN, Yazdanfar S: Stimulation of coronary collateral growth: current developments in angiogenesis and future clinical applications. Am Heart J 1992;123(2):486-496
13. Lefer AM, Peck RC: Cardioprotective effects of enalapril in acute myocardial ischemia. Pharmacol 1984; 29:61-69
14. Hock CE, Ribeiro GT, Lefer AM: Preservation of ischemie myocardium by a new converting enzyme inhibitor, enalaprilic acid, in acute myocardial infarction. Am Heart J 1985; 109:222-228
15. Stauss HM, Zhu YC, Redlich T, Unger T: Early and late treatment of infarction-induced heart failure with a converting enzyme inhibitor: Bradykinin potentiation versus angiotensin II reduction. Hypertension 1993;22(3):429(abstract)
16. Stauss HM, Zhu YC, Redlich T, Adamiak D, Mott A, Kregel KC, Unger T: ACE inhibition in infarct-induced heart failure, bradykinin versus angiotensin II. J Cardiovasc Risk 1994; 1:255-262
17. Stauss HM, Zhu YC, Redlich T, Adamiak D, Moot A, Unger T: Mechanism involved in the reduction of infarct size by ACE inhibition after left coronary ligation in rats. J Hypertens 1994; 12 (suppl 13):S2 (abstract)
18. Duncan AM, Burell LM, Kladis A, Campbell DJ: Effects of angiotensin-converting enzyme inhibition on angiotensin and bradykinin peptides in rats with myocardial infarction. J Cardiovasc Phamacol 1996; 28:746-754
19. Linz W, Schölkens BA: A specific B2-bradykinin receptor antagonist HOE 140 abolishes the antihypertrophic effect of ramipril. Br J Pharmacol 1992;105:771-772
20. Gohlke P, Linz W, Schölkens BA, Kuwer I, Bartenbach S, Schnell A, Unger T: Angiotensin converting enzyme inhibition improves cardiac function: role of bradykinin. Hypertension 1994;23:411-418
21. Unger T, Mattfeldt T, Lamberty V, Bock P, Mall G, Linz W, Schölkens BA, Gohlke P: Effect of early onset angiotensin converting enzyme inhibition on myocardial capillaries. Hypertension 1992;20:478-482